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Abstract
A large number of rare sequence variants of unknown clinical significance have been identified in the breast cancer
susceptibility genes, BRCA1 and BRCA2. Laboratory-based methods that can distinguish between carriers of pathogenic
mutations and non-carriers are likely to have utility for the classification of these sequence variants. To identify predictors of
pathogenic mutation status in familial breast cancer patients, we explored the use of gene expression arrays to assess the
effect of two DNA–damaging agents (irradiation and mitomycin C) on cellular response in relation to BRCA1 and BRCA2
mutation status. A range of regimes was used to treat 27 lymphoblastoid cell-lines (LCLs) derived from affected women in
high-risk breast cancer families (nine BRCA1, nine BRCA2, and nine non-BRCA1/2 or BRCAX individuals) and nine LCLs from
healthy individuals. Using an RNA–pooling strategy, we found that treating LCLs with 1.2 mM mitomycin C and measuring
the gene expression profiles 1 hour post-treatment had the greatest potential to discriminate BRCA1, BRCA2, and BRCAX
mutation status. A classifier was built using the expression profile of nine QRT–PCR validated genes that were associated
with BRCA1, BRCA2, and BRCAX status in RNA pools. These nine genes could distinguish BRCA1 from BRCA2 carriers with 83%
accuracy in individual samples, but three-way analysis for BRCA1, BRCA2, and BRCAX had a maximum of 59% prediction
accuracy. Our results suggest that, compared to BRCA1 and BRCA2 mutation carriers, non-BRCA1/2 (BRCAX) individuals are
genetically heterogeneous. This study also demonstrates the effectiveness of RNA pools to compare the expression profiles
of cell-lines from BRCA1, BRCA2, and BRCAX cases after treatment with irradiation and mitomycin C as a method to prioritize
treatment regimes for detailed downstream expression analysis.
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Introduction
Rare sequence variants in BRCA1 and BRCA2 that are not
predicted to lead to obvious or easily detectable molecular
aberrations, such as protein truncation or RNA splicing defects,
are currently difficult to classify clinically as pathogenic or neutral.
These variants attribute to approximately 10% of clinical test
results, and create a significant challenge for counseling and
clinical decision making when identified in patients with a strong
family history of breast cancer. Laboratory based methods that can
distinguish between carriers of known pathogenic mutations and
non-carriers are likely to have utility for the classification of
sequence variants of unknown clinical significance.
Expression profiling has been used successfully to characterize
molecular subtypes in breast cancer whether based on gene
expression patterns in primary tumor cells [1–3], metastatic cells
[4], or stroma-derived cells [5]. Distinctive patterns of global gene
expression have also been shown between breast tumors with
BRCA1 mutations and breast tumors with BRCA2 mutations [6].
More recently, evidence has been presented from several studies to
suggest that heterozygous carriers of BRCA1 and BRCA2
mutations, and breast cancer patients without such alterations
may be distinguished based on mRNA profiling of fibroblasts and
lymphoblastoid cell-lines (LCLs) [7–9]. In one study, short-term
breast fibroblast cell-lines were established from nine individuals
with a BRCA1 germ-line mutation, and five healthy control
individuals with no personal or family history of breast cancer [7].
Class prediction analysis using expression data from irradiated
fibroblast cultures showed that BRCA1 carriers could be
distinguished from controls with 85% accuracy [7]. A similar
study used short-term fibroblast cultures from skin biopsies from
10 BRCA1 and 10 BRCA2 mutation carriers and 10 individuals
who had previously had breast cancer but were unlikely to contain
BRCA1/2 mutations [8]. Class prediction analysis using expression
data from irradiated fibroblast cultures showed that BRCA1 and
BRCA2 samples could be classified with 95% accuracy, and
BRCA1/2 carriers could be distinguished from noncarriers with
90% to 100% accuracy [8].
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cell-lines (LCLs) are a minimally invasive source of germline
material that can be maintained as long term culture, and which
have proven to be a valuable model system for studying gene
expression signatures in relation to genetic variation and external
stimulants [10–13]. A recent study from our laboratory utilizing
this model system suggested that post-irradiation (IR) gene
expression data from LCLs derived from blood of patients with
sequence alterations in BRCA1 and BRCA2, and from familial
breast cancer patients without such alterations (BRCAX) has
potential to predict BRCA1, BRCA2 and BRCAX mutation status
with up to 62% accuracy [9]. In view of improving prediction
accuracy, especially between BRCA1 and BRCA2, we used
expression arrays to assess the effect of the DNA damaging
agents, IR and mitomycin C (MMC), at different time points, on
cellular response in relation to mutation status. To facilitate
analysis of the large number of treated LCLs, an RNA pooling
strategy was implemented to reduce the number of microarray
experiments by three-fold. Previous studies have used RNA
pooling as a strategy to reduce the effects of biological variation
in order to help identify key features that differ between biological
class [14,15]. We have therefore explored a similar approach in
this study using patient derived LCLs as well as prior knowledge
that LCL expression profiles are influenced by both genotype and
exogenous factors. This strategy was shown to be effective in
identifying genes dysregulated in response to DNA damaging
agents. This study also demonstrated the effectiveness of RNA
pools to compare the effect of various IR and MMC treatment
regimes on the mRNA expression profiles of LCLs derived from
BRCA1, BRCA2 and BRCAX cases for downstream detailed
analysis of individual samples.
Results
Effect of IR and MMC on global gene expression
To identify which treatment caused the greatest amount of
change in gene expression levels, we first determined the number
of genes that showed differential expression between pools for each
treatment, particularly for BRCA1 versus BRCA2 and BRCA1 versus
BRCAX (Figure 1). Using fold-change as a measure of differential
gene expression revealed that the number of genes differentially
expressed (.2-fold) between BRCA1, BRCA2 and BRCAX pools
after IR was similar to that shown by the untreated controls
(Figure 1A). However, significant differences in the expression of
genes acting in the IR-induced ATM signaling pathway was
Author Summary
A large number of rare sequence variants of unknown
clinical significance have been identified in the breast
cancer susceptibility genes, BRCA1 and BRCA2. Laboratory
methods to identify which of these variants are mutations
would have utility for counseling and clinical decision
making when identified in patients with a family history of
breast cancer. We used DNA–damaging agents to disturb
gene expression profiles of cell-lines derived from blood of
patients, and we compared patterns from women with
BRCA1 and BRCA2 mutations to women familial breast
cancer families without such mutations. Using a pooling
strategy, which allowed us to compare several treatments
at one time, we identified which treatment caused the
greatest difference in gene-expression changes between
patient groups and used this treatment method for further
study. We were able to accurately classify BRCA1 and
BRCA2 samples, and our results supported other reported
findings that suggested familial breast cancer patients
without BRCA1/2 mutations are genetically heterogeneous.
We demonstrate a useful strategy to identify treatments
that induce gene expression differences associated with
BRCA1/2 mutation status. This strategy may aid the
development of a molecular-based tool to screen individ-
uals from multi-case breast cancer families for the
presence of pathogenic mutations.
Figure 1. Number of genes differentially expressed among BRCA1, BRCA2, and BRCAX. Differential expression was determined by (A) fold-
change (geometric mean of the expression ratios .2), and (B) statistical correlation using the F-test and alpha levels 0.05 and 0.01.
doi:10.1371/journal.pgen.1000850.g001
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pools (Figure S1), confirming inducement of an expression
phenotype by IR. Of the four MMC treatments, the number of
genes differentially expressed between pools was greatest when
LCLs were treated with 1.2 mM MMC and the RNA isolated 1
hour post-treatment (Figure 1A). There is currently no canonical
or consensus pathway based on MMC activity. It was therefore
not possible to confirm the effects of this treatment by assessing
expression phenotypes.
Identifying which treatment produced expression change in the
greatest number of genes was also carried out by performing an F-
test separately for each gene and determining the number of genes
differentially expressed with significance levels set at 0.05 and 0.01
(Figure 1B). LCLs treated with MMC showed the greatest
expression change after 1 hour incubation, with a slightly bigger
effect associated with 1.2 mM MMC versus 0.4 mM MMC, thus
suggesting that MMC has a greater perturbation effect after the
shorterincubationperiod(Figure1B).A similartrend inthe number
of genes differentially expressed between classes was observed when
the significance level was set at 0.001 (Data not shown). Overall,
these results indicated that, of the treatments used, 1.2 mM
MMC(T60) was most likely to induce gene expression profiles that
differ significantly between BRCA1, BRCA2 and BRCAX LCLs.
Identification of MMC responsive genes that discriminate
BRCA1, BRCA2, and BRCAX mutation type
To identify genes that would discriminate pools based on
mutation status, three comparative analyses were performed to
achieve threeobjectives.The first objectivewas toidentifygenesthat
were differentially expressed between BRCA1, BRCA2 and BRCAX
pools treated with 1.2 mMM M C ( T 60). This analysis identified 699
genes that are able to discriminate pools based on mutation status
(Figure 2A, Table S1). The second objective was to identify genes
that were differentially expressed between treated 1.2 mM
Figure 2. Classifying BRCA1, BRCA2, and BRCAX subtype by MMC response genes. (A) Venn diagram illustrating the number of genes
identified from three analyses: 1) 3-way comparison of BRCA1, BRCA2 and BRCAX pools (F-test, P,0.05); 2) Pairwise comparison of 1.2 mM MMC-T60
treated and non-treated BRCA1/2/X pools (,10% false discovery rate; 90% confidence level); and 3) 2-way comparison of 1.2 mM MMC-T60 treated and
non-treated healthy control pools (T-test, P,0.05). The extent of overlap between gene lists is shown. (B) List of 36 genes that are differentially
expressed between BRCA1, BRCA2, and BRCAX, and are MMC responsive in affected carrier pools but not in healthy controls. (C) Supervised
hierarchical clustering of treated (1.2 mM MMC-T60) sample pools using the 36-gene list.
doi:10.1371/journal.pgen.1000850.g002
Expression Profiles Related to BRCA1/2 Mutations
PLoS Genetics | www.plosgenetics.org 3 February 2010 | Volume 6 | Issue 2 | e1000850MMC(T60) and non-treated BRCA1, BRCA2 and BRCAX pools.
The 1911 genes identified from this analysis werethen characterized
as MMC responsive (Figure 2A, Table S1). Combining these two
analyses revealed 50 genes that classified pools based on mutation
status and that are also MMC responsive (Figure 2A). The third
objective was to identify genes that were differentially expressed
between treated (1.2 mMM M C ( T 60)) and non-treated healthy
control pools. This analysis was important to identify genes that are
MMC responsive in healthy controls and therefore not specific for
mutation status in BRCA1, BRCA2 and BRCAX pools (Figure 2A,
Table S1). By combining the results of these three analyses, 36 genes
were identified that are differentially expressed between BRCA1,
BRCA2 and BRCAX pools, and are also MMC responsive in
affected carrier pools but not in healthy controls (Figure 2A and 2B).
As expected, supervised hierarchical clustering of 1.2 mM
MMC(T60) treated and non-treated pools using the 36-gene list
demonstrates a separation of treated pools based on mutation type,
but no separation by mutation type was observed in untreated pools
(Figure 2C). Likewise, there was no discrimination of treated and
untreated healthy control pools (Figure 2C).
QRT-PCR was carried out to validate the expression levels of
the 36 MMC responsive genes in the BRCA1, BRCA2, and
BRCAX derived RNA pools. Despite relatively small fold-changes
detected in pools for each of the 36 genes between the three
mutation groups, 15 genes were validated by QRT-PCR (Table 1);
three times more than that expected by chance.
Of these 15 genes, nine also showed high correlation (r.0.6) in
expression level between microarray and the QRT-PCR value of
the same RNA pools (Table 1). These nine MMC responsive genes
were therefore selected for class prediction tests.
Comparison of RNA pools and virtual pools
To explore potential technical variation associated with
generating RNA pools, we compared expression levels of the nine
MMC responsive genes, measured by microarray and QRT-PCR
analysis in the nine RNA pools, and by QRT-PCR in the 27
individual LCL samples. Virtual pools were also generated by
taking the average of QRT-PCR expression values from the
individual samples used in the pools. Figure 3 shows that the
coefficient of variation (CV) differed between the nine genes
regardless of the experiment strategy. The least amount of
variation from measured gene expression tended to be observed
after microarray analysis of RNA pools with the CV ranging from
0.05 to 0.49 for the nine validated genes (Figure 3). In contrast, the
greatest amount of variation from measured gene expression
tended to be observed after QRT-PCR analysis of individual RNA
samples with the CV of the same genes ranging from 0.33 to 1.11
(Figure 3). Similar gene expression variation was observed between
RNA pools (CV ranged from 0.16 to 0.76) and virtual pools (CV
ranged from 0.16 to 0.78), with the exception of FAM26F
(Figure 3). Moreover, the correlation of expression data between
the RNA pools and virtual pools was greater than 0.7 for seven of
the nine genes analyzed (Table S2). These results suggest that
although pooling reduces measured variation in expression levels,
this reduction is most likely the result of a biological averaging
effect and not technical issues relating to the different steps
involved in the microarray experiment.
Class prediction of BRCA1, BRCA2, and BRCAX mutation
status using nine MMC responsive genes
We utilized five different prediction methods (Diagonal Linear
Discriminant Analysis, 1-Nearest Neighbour and Nearest Centroid
classification, Support Vector Machines, and Compound Covar-
iate Predictor) to determine the accuracy of using the nine MMC
responsive genes to predict the three biological classes (BRCA1
truncation mutation, BRCA2 truncation mutation, and BRCAX)
by means of a three-way comparison (Details shown in Tables S3,
S4). If the nine genes selected for classification are related to MMC
Table 1. Fifteen QRT–PCR validated genes shown to be differentially expressed among BRCA1, BRCA2, and BRCAX pools, and MMC
responsive in affected carrier pools but not in healthy controls.
Gene Symbol BRCA1/BRCA2
a BRCA1/BRCAX
a BRCA2/BRCAX
a
Pearson’s
correlationb
Microarray QRT-PCR Microarray QRT-PCR Microarray QRT-PCR
SLC6A4 1.08 1.23 0.66 0.52 0.61 0.43 0.95
FAM26F 0.39 0.60 0.63 0.94 1.63 1.55 0.83
CCDC151 0.51 0.51 0.48 0.50 0.95 0.99 0.80
RARSL 1.14 1.32 1.00 1.18 0.88 0.90 0.75
P4HA2 0.61 0.49 0.97 0.65 1.60 1.33 0.70
LMNA 1.47 1.27 1.82 1.71 1.24 1.35 0.68
CASP3 1.56 1.28 1.30 1.03 0.83 0.81 0.67
GPM6A 0.91 0.34 0.94 0.75 1.04 2.18 0.61
CDCP1 0.98 0.81 1.18 2.14 1.21 2.63 0.61
CEND1 1.10 1.20 0.86 0.80 0.79 0.67 0.48
TNFRSF13C 0.59 0.95 0.66 0.98 1.13 1.04 0.47
HES4 0.38 0.58 0.69 0.69 1.82 1.19 0.47
CHCHD4 1.01 1.07 0.75 0.87 0.74 0.81 0.42
HSPA1L 0.87 0.83 0.83 0.79 0.96 0.95 0.35
GRHL1 0.96 0.81 0.83 0.70 0.87 0.86 0.34
a Ratio of the average expression level.
b Correlation between microarray and QRT–PCR expression data from nine RNA pools. Nine genes with a Pearson’s correlation greater than 0.6 are shown in bold.
doi:10.1371/journal.pgen.1000850.t001
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treated groups compared to non-treated and IR treated group.
Interestingly, BRCA1, BRCA2 and BRCAX pools were poorly
classified from the IR(T60) (44%–78%) and T0 (33%–56%)
treatments groups compared to the four MMC treated groups
(67%–100%) using microarray data from the nine MMC
responsive genes (Table S5). Results from the class prediction
analysis of 1.2 mM MMC(T60) treated pools and individual
samples are shown in Table 2. Not surprisingly, the highest
accuracy (67%–100%) for predicting BRCA1, BRCA2 and
BRCAX mutation status of pools was achieved using microarray
data (Table 2). By comparison, performing the same analysis on
BRCA1, BRCA2 and BRCAX pools using QRT-PCR derived
expression data achieved an accuracy of 56%-78% in predicting
mutation type for each of the pooled RNAs (Table 2).
Prediction analysis with QRT-PCR data from the 27 individual
LCL samples used to derive the nine BRCA1, BRCA2, and
BRCAX associated pools correctly classified the individual
samples with up to 59% accuracy using the NC model (Table 2).
Similar to the results shown using QRT-PCR data from the RNA
pools, classification of the virtual pools was typically lower than
that seen with the microarray data but higher than that achieved
when analyzing the individual samples (Table 2). In addition to the
three-way comparison, we also performed a series of two-way
comparisons to explore the accuracy of the nine MMC responsive
genes to classify both pools and individual samples (Details shown
in Tables S6, S7, S8, S9, S10, S11). Notably, these genes were
sufficient to classify BRCA1 versus BRCA2 pools with 100%
accuracy, with a slightly reduced prediction accuracy of 83%
within the individual samples for all models (Table 2). Classifica-
tion was lowest when comparing BRCAX and BRCA1 samples
(56%–67%), or BRCAX and BRCA2 samples (44%–72%)
(Table 2). Although the DLDA classifier performed well using
microarray derived expression values from BRCA1, BRCA2 and
BRCAX pools, the model performed relatively poorly when
classifying individual samples with greater than 50% misclassifi-
Figure 3. The coefficient of variation (i.e. standard deviation divided by the mean) of the expression values for the nine MMC
responsive genes. For each gene, microarray and/or QRT–PCR derived data are compared across RNA pools, virtual pools and individual samples.
doi:10.1371/journal.pgen.1000850.g003
Table 2. Accuracy of class prediction based on the expression profile of nine MMC responsive genes.
Class Expression data sourcea Mean percent of correct classification
DLDA 1-NN NC SVM CCP
BRCA1 vs BRCA2 vs BRCAX Pools (Microarray) 100% 67% 89% – –
Pools (QRT-PCR) 56% 67% 78% – –
Virtual Pools (QRT-PCR) 78% 89% 67% – –
Samples (QRT-PCR) 48% 52% 59% – –
BRCA1 vs BRCA2 Pools (Microarray) 83% 100% 100% 100% 100%
Pools (QRT-PCR) 100% 100% 100% 83% 100%
Virtual Pools (QRT-PCR) 100% 100% 100% 100% 100%
Samples (QRT-PCR) 83% 83% 83% 83% 83%
BRCA1 vs BRCAX Pools (Microarray) 100% 100% 100% 100% 100%
Pools (QRT-PCR) 67% 83% 67% 83% 67%
Virtual Pools (QRT-PCR) 83% 100% 83% 100% 83%
Samples (QRT-PCR) 56% 56% 67% 56% 56%
BRCA2 vs BRCAX Pools (Microarray) 100% 50% 83% 83% 100%
Pools (QRT-PCR) 67% 67% 83% 50% 67%
Virtual Pools (QRT-PCR) 33% 83% 67% 67% 83%
Samples (QRT-PCR) 44% 72% 72% 61% 72%
a Pools, n=9; Samples, n=27. Abbreviations: CCP, Compound covariate predictor; DLDA, Diagonal Linear Discriminant Analysis; NC, Nearest Centroid; 1-NN, Nearest
Neighbour; SVM, support vector machine.
doi:10.1371/journal.pgen.1000850.t002
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individual samples was the Nearest Centroid model which gave
the highest prediction accuracy (59%) for BRCA1, BRCA2 and
BRCAX mutation type. Furthermore, this model successfully
classified the majority of individual samples from two-way
comparisons of BRCA1 versus BRCA2 (83%), BRCA1 versus BRCAX
(67%), and BRCA2 versus BRCAX (72%).
Discussion
We have recently reported a study using expression profiling of
IR treated LCLs to predict the mutations status of BRCA1 and
BRCA2 with the ultimate aim of predicting the significance of
unclassified variants of BRCA1 and BRCA2 [9]. Using similar
rationale, the present study explores the use of treatment regimes
that employ the DNA damaging agents, IR and MMC, with the
aim to increase the prediction accuracy from that reported by
Waddell et al, especially between BRCA1 and BRCA2 [9].
Furthermore, this study demonstrates the use of RNA pools to
compare the effect of five different IR or MMC treatment regimes
on the expression profiles of LCLs derived from BRCA1, BRCA2
and BRCAX cases.
Our results from analysis of RNA pools suggested that treating
LCLs with 1.2 mM MMC and measuring the gene expression
profiles 60 minutes post-treatment had the greatest potential to
discriminate BRCA1, BRCA2 and BRCAX mutation status. We
subsequently built a classifier using the expression of nine genes
that were responsive to the 1.2 mM MMC(T60) treatment regime.
Leave-one-out-cross-validation to the whole procedure was not
possible with the current study design given that the 9-gene
classifier was derived in two stages: 1) from the intersection of three
gene lists from three separate analyses, and 2) from only those
genes confirmed by QRT-PCR. We acknowledge that overfitting
could play a role in this study, and for this reason we used a
stringent filtering approach as outlined in Figure 1. The highest
prediction accuracy achieved using the 9-gene classifier for
individual BRCA1, BRCA2 and BRCAX samples (59%) was
similar to that previously reported by Waddell et al (62%) [9],
although due to differences in experimental design we cannot
exclude the possibility that the prediction accuracy from the latter
study may have been influenced by an experimentally induced
bias. Importantly, our results showed that after treatment with
MMC, BRCA1 and BRCA2 samples were shown here to be more
dissimilar than either BRCA1 or BRCA2 was from BRCAX.
Furthermore, in contrast to Waddell et al [9], BRCA1 and BRCA2
samples were classified with high accuracy, thus supporting the
notion that LCLs harboring pathogenic mutations in BRCA1 and
BRCA2 have a distinctive expression. Together these results
suggest that compared to BRCA1 and BRCA2 truncating mutation
carriers BRCAX comprises a genetically heterogeneous group that
requires further molecular-based stratification. This notion is also
consistent with linkage studies [16] as well as molecular studies
that suggested BRCAX tumors can be classified into at least five
molecular subtypes [17,18]. It is therefore reasonable to propose
that the accuracy of classifying pathogenic sequence variants in
LCLs by expression profiling will improve as molecular subgroups
within BRCAX individuals are identified.
An important method employed by this microarray-based study
was the use of RNA pooling primarily to reduce cost. Studies have
also used RNA pooling as a strategy to reduce the effects of
biological variation with the aim of detecting gene expression
profiles that differ between biological class [14,15]. A disadvantage
with pooling RNA is the impact it may have on statistical power in
identifying genes that are differentially expressed between two or
more classes [19,20]. This is because pooling RNA prevents both
accurate measurement of expression variation within the sample
population and identification of deviant samples. Pooling has been
shown to be most useful when the gene expression differences
between biological conditions are larger than differences intro-
duced by technical variability [21–23]. LCLs analyzed in the
present study showed relatively low biological variation between
pools for many of the genes analyzed, including the nine genes
found to be 1.2 mM MMC(T60)-responsive. Expression differences
between the biological classes studied were therefore more prone
to variance introduced at each step of the microarray experiment.
These small differences may account in part for the reduced
classification accuracy observed using expression values measured
by QRT-PCR as compared to the same analysis using microarray
data. However, it is worth noting that we generally observed good
correlation between the RNA pools and virtual pools for the
expression differences (Table S2), supporting the use of pooling
sample RNA for initial microarray experiments to direct
downstream analysis of individual samples.
Previous studies have suggested MMC may perturb the Fanconi
anemia pathway, in which BRCA2 plays a major role [24].
Interestingly, the protein encoded by one of the nine MMC
responsive genes, CASP3, is known to be activated by the Fanconi
anemia pathway as result of MMC or IR treatment [25]. The
nuclear lamina protein LMNA has also been shown to play a role
in ATR mediated DNA repair [26] and through this role may
interact with BRCA1 and/or BRCA2 in response to MMC
induced DNA damage [27]. It is unclear at this stage whether the
remaining seven MMC responsive genes play a role in the Fanconi
anemia pathway, and how they are functionally linked to BRCA1
and/or BRCA2. It is possible that unmapped BRCA1- and/or
BRCA2-related pathways are also being perturbed by MMC
treatment. An intriguing thought is the possibility that these genes
may act as potential modifiers of BRCA1 and/or BRCA2 associated
breast cancer risk. We have previously reported a novel method of
using expression arrays and the Cancer Genetic Markers of
Susceptibility (CGEMS) Breast Cancer Whole Genome Associa-
tion Scan to prioritize IR response genes that potentially modify
breast cancer risk in BRCA1 and BRCA2 carriers [28]. It is
interesting to note that of the nine 1.2 mM MMC(T60)-responsive
genes, GPM6A and CDCP1 are tagged with single nucleotide
polymorphisms that are shown by CGEMS to be associated with
breast cancer risk (P,0.05) (data not shown). Furthermore,
deletions of chromosome regions harboring GPM6 (4q34.2),
CASP3 (4q35.1), and P4HA2 (5q23.3) have been shown to be
associated with breast tumors from BRCA1 mutation carriers [29–
31,18]. Likewise, genomic regions harboring RARSL (6q15) and
FAM26F (6q22.1) have been frequently deleted in BRCA2
associated breast tumors [31]. These results give rise to an
intriguing possibility that GPM6, CASP3, P4HA2, RARSL and
FAM26F may also be targeted during breast tumorigenesis as the
tumor cells undergo genomic copy number change.
In summary, our results demonstrate the use of RNA pooling
and microarray profiling to assess LCLs derived from patients with
a strong family history of breast cancer. This study highlights the
novel use of MMC to perturb LCL expression profiles to identify
genes that correlate with BRCA1, BRCA2 and BRCAX mutation
status. This strategy proved promising for classifying mutation
status by gene expression profile, particularly between BRCA1 and
BRCA2, and prediction accuracy may be improved further by
exploring different MMC doses and/or analysis time points. We
propose that the pooling method is the most practical approach for
comparing a number of different treatment regimes across several
different sample sets. This strategy is likely to be very useful for
Expression Profiles Related to BRCA1/2 Mutations
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in LCLs after stimulation. Identifying genes whose expression is
associated with BRCA1, BRCA2 and BRCAX mutation status
would be a valuable method of screening individuals from multiple
case breast cancer families for the presence of pathogenic
mutations.
Materials and Methods
Ethics statement
Ethical approvals were obtained from the Human Research
Ethics Committees of the Queensland Institute of Medical
Research and the Peter MacCallum Cancer Centre. Written
informed consent was obtained from each participant.
Subjects and lymphoblastoid cell-lines
Epstein Barr virus-transformed lymphoblastoid cell-lines (LCLs)
were derived from breast cancer-affected women in multi-case
families recruited into the Kathleen Cuningham Foundation for
Research into Breast Cancer (kConFab) [32] and from healthy
female controls recruited as volunteers from the Queensland
Institute of Medical Research. A cohort of 36 LCLs were used in
this study, including nine LCLs from women carrying a
pathogenic mutation in BRCA1, nine LCLs from women carrying
a pathogenic mutation in BRCA2, nine LCLs from women from
breast cancer families that have tested negative for pathogenic
mutations in BRCA1 or BRCA2 (termed BRCAX), and nine LCLs
from healthy control females. Details of the mutations carried by
each of the LCLs used in the study are shown in Table S12.
LCL culture and treatment
LCLs were cultured in RPMI-1640 (Gibco Invitrogen) supple-
mented with 10% Serum Supreme (Lonza BioWhittaker), 1%
penicillin-streptomycin (Gibco Invitrogen). Cell number was
normalized to a density of 5610
5 cells/mL, approximately 4 h
prior to treatment. To extend a previous study where gene
expression levels were measured in LCLs after 10 Gy IR and 30
minute incubation [9], this study aims to identify IR responsive
genes after an equivalent IR dose but at 60 minutes post-
treatment. The MMC treatments were selected based on previous
reports that showed LCLs carrying a mutation in the BRCA2 gene
were sensitive to MMC at 0.05 mM - 1.2 mM after 1–2 hours
incubation [33,34]. In this study, LCLs from each of the BRCA1,
BRCA2 and BRCAX patient groups, and from healthy controls,
were irradiated at 10 Gy using a calibrated Cesium-137 source or
treated with MMC at two different doses (0.4 mM or 1.2 mM).
Cells were harvested prior to IR or MMC treatment (T0), at 1 h
after IR exposure, and at 1 and 2 h after exposure for MMC.
Microarray expression profiling
Total RNA was extracted and purified using the RNeasy Mini
Kit (Qiagen GmbH). Three RNA pools were generated within
each group (BRCA1, BRCA2, BRCAX and healthy controls) that
comprised RNA (1000 ng) from each of three individual samples.
RNA was quantified pre- and post-pooling using the NanoDrop
ND-1000 spectrophotometer (Thermo Scientific). A comparison of
estimated and observed RNA concentrations associated with each
pool is detailed in Table S13. This procedure was carried out for
each of the six treatment groups (including T0), thus generating a
total of 72 RNA pools. The Illumina TotalPrep RNA Amplifica-
tion Kit (Ambion) was used to amplify and biotinylate 450 ng of
total RNA from each of the pools. Biotinylated RNA was
hybridized to Illumina HumanRef8-V2 Beadchips (,22,000
probes), washed, and stained with streptavidin-Cy3 before
scanning with an Illumina BeadArray Reader. The RNA pools
were processed in random order to minimize any chance of
technical bias being introduced into the microarray data.
Duplicate arrays were performed for eight pools to test for
reproducibility, and a high correlation (r
2.0.99) was measured
within each paired-pool comparison. Only one of each duplicated
sample was included in subsequent analyses.
Microarray data analysis
Raw data were processed using Illumina BeadStudio before
undergoing quantile normalization to account for systematic
variation between arrays. Microarray data are available via
GEO: GSE17764. Probes that obtained an Illumina detection
score greater than 0.99 in at least one of the arrays (n=16,478
probes) were retained for further analysis. Subsequent statistical
analysis of genes differentially expressed between RNA-pools,
classified by mutation and treatment type, was carried out using
BRB-ArrayTools version 3.7.0 (http://linus.nci.nih.gov/BRB-
ArrayTools.html). Genes differentially expressed between BRCA1,
BRCA2 and BRCAX pools, and between treated and untreated
LCL pairs of healthy control pools were evaluated using three-
sample F-tests and paired T-tests, respectively (a=0.05). Micro-
array expression profiles of the treated and untreated LCL pairs of
BRCA1, BRCA2 and BRCAX pools were compared using paired
T-tests and the number of false discoveries was restricted to 10%
at a 90% confidence level using methods described elsewhere
[35,36].
Quantitative reverse transcription–PCR
First-strand cDNA synthesis was performed using 450 ng of
total RNA and SuperScript III First-Strand Synthesis System for
RT-PCR (Invitrogen), according to manufacturer’s instructions.
Quantitative reverse transcription PCR (QRT-PCR) was per-
formed using Platinum SYBR Green qPCR SuperMix-UDG
(Invitrogen) and the LightCycler480 system (Roche Applied
Science). Briefly, each 15 mL reaction contained 1x Platinum
SYBR Green qPCR SuperMix-UDG, and 333 nM of each
primer. Primer sequences are listed in Table S14. For each gene,
primers sequences were designed to target at least one exon
detected by the Illumina HumanRef8-V2 Beadchip probe
sequence. QRT-PCR conditions were as follows: 50uC for 2
minutes, 95uC for 2 minutes, and then 45 cycles of 95uC for 20
seconds, 60uC for 15 seconds and 72uC for 20 seconds. All QRT-
PCR reactions were done in triplicate. The data were normalized
to the housekeeping gene EEF1A1 and log2-transformed for
further analysis.
Class prediction with microarray and QRT–PCR data
Class prediction was performed using Diagonal Linear Dis-
criminant Analysis [37], K-Nearest Neighbour Classification [37],
Nearest Centroid [38], Support Vector Machines (SVM) [39], and
Compound Covariate Predictor [40] algorithms in BRB-Array-
Tools version 3.7.0. The K-Nearest Neighbour method used one
nearest neighbour (k=1), and the linear kernel method was used
for Support Vector Machines. The models incorporated MMC
responsive genes confirmed by QRT-PCR (see Results) that were
differentially expressed between BRCA1, BRCA2 and BRCAX
classes. Leave-one-out cross-validation method was used to
compute misclassification rate [41].
Supporting Information
Figure S1 Supervised cluster analysis of IR treated (IR T60) and
non-treated (T0) RNA pools from BRCA1 and BRCA2 mutation
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(HC) individuals using 19 genes (ATM, BRCA1, CDKN1A, CHEK1,
CHEK2, GADD45A, JUN, MAPK8, MDM2, MRE11A, MTTP,
NBN, NFKB1, NFKBIA, RAD50, RAD51, RBBP8, TP53, TP73)
comprising the ATM Signaling Pathway (Biocarta).
Found at: doi:10.1371/journal.pgen.1000850.s001 (0.11 MB TIF)
Table S1 List of genes and their associated significance levels
from three different analyses.
Found at: doi:10.1371/journal.pgen.1000850.s002 (0.52 MB
XLS)
Table S2 Correlation of QRT-PCR derived expression data
between pools and virtual pools.
Found at: doi:10.1371/journal.pgen.1000850.s003 (0.05 MB
DOC)
Table S3 Performance of classifier with BRCA1, BRCA2, and
BRCAX pools during cross-validation.
Found at: doi:10.1371/journal.pgen.1000850.s004 (0.05 MB
DOC)
Table S4 Predictions of classifiers for BRCA1, BRCA2, and
BRCAX virtual pools and samples.
Found at: doi:10.1371/journal.pgen.1000850.s005 (0.06 MB
DOC)
Table S5 Correct classification rates of BRCA1, BRCA2, and
BRCAX pools using microarray data from the various treatment
groups and the nine 1.2 mM MMC(T60)-responsive genes.
Found at: doi:10.1371/journal.pgen.1000850.s006 (0.03 MB
DOC)
Table S6 Performance of classifier with BRCA1 and BRCA2
pools during cross-validation.
Found at: doi:10.1371/journal.pgen.1000850.s007 (0.05 MB
DOC)
Table S7 Predictions of classifiers for BRCA1 and BRCA2 virtual
pools and samples.
Found at: doi:10.1371/journal.pgen.1000850.s008 (0.06 MB
DOC)
Table S8 Performance of classifier with BRCA1 and BRCAX
pools during cross-validation.
Found at: doi:10.1371/journal.pgen.1000850.s009 (0.05 MB
DOC)
Table S9 Predictions of classifiers for BRCA1 and BRCAX
virtual pools and samples.
Found at: doi:10.1371/journal.pgen.1000850.s010 (0.06 MB
DOC)
Table S10 Performance of classifier with BRCA2 and BRCAX
pools during cross-validation.
Found at: doi:10.1371/journal.pgen.1000850.s011 (0.05 MB
DOC)
Table S11 Predictions of classifiers for BRCA2 and BRCAX
virtual pools and samples.
Found at: doi:10.1371/journal.pgen.1000850.s012 (0.06 MB
DOC)
Table S12 Details of mutations carried by each LCL used in the
study and pool assignment.
Found at: doi:10.1371/journal.pgen.1000850.s013 (0.05 MB
DOC)
Table S13 Comparison of estimated and observed RNA
concentrations associated with each pool analysed.
Found at: doi:10.1371/journal.pgen.1000850.s014 (0.04 MB
DOC)
Table S14 QRT-PCR primer details.
Found at: doi:10.1371/journal.pgen.1000850.s015 (0.05 MB
DOC)
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